Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Cullinan Therapeutics, Inc. (CGEM) had Income from Continuous Operations of $-50.61M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-50.61M |
|
-- |
|
-- |
|
$55.59M |
|
$-55.59M |
|
$4.99M |
|
$-50.61M |
|
$-50.61M |
|
$-50.61M |
|
|
Income from Continuous Operations |
$-50.61M |
$-50.61M |
|
$-50.61M |
|
$-55.59M |
|
$-55.52M |
|
59.08M |
|
59.08M |
|
$-0.77 |
|
$-0.77 |
|
| Balance Sheet Financials | |
$342.24M |
|
$0.49M |
|
$141.89M |
|
$484.13M |
|
$32.76M |
|
-- |
|
-- |
|
$32.76M |
|
$451.37M |
|
$451.37M |
|
$451.37M |
|
59.08M |
|
| Cash Flow Statement Financials | |
$-137.64M |
|
$157.60M |
|
$0.37M |
|
$83.00M |
|
$103.33M |
|
$20.33M |
|
$28.73M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-137.68M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.21% |
|
-11.21% |
|
-10.45% |
|
-11.21% |
|
$7.64 |
|
$-2.33 |
|
$-2.33 |
|